Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 1, 2006, Pages 345-351

  Bumpus, Namandjé N ^a   Kent, Ute M ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYEFAVIRENZ; AMFEBUTAMONE; ANTIVIRUS AGENT; COUMARIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DRUG METABOLITE; EFAVIRENZ; HEME; MUTANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DIALYSIS; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME SUBSTRATE; HYDROXYLATION; PRIORITY JOURNAL; WILD TYPE;

AMINO ACID SUBSTITUTION; ARYL HYDROCARBON HYDROXYLASES; ENZYME ACTIVATION; HUMANS; OXAZINES; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 33745268491     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.102525     Document Type: Article

References (38)

1. Blobaum AL, Kent UM, Alworth WL, and Hollenberg PF (2002) Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. Chem Res Toxicol 15:1561-1571.
2. Blobaum AL, Lu Y, Kent UM, Wang S, and Hollenberg PF (2004) Formation of a novel reversible cytochrome P450 spectral intermediate role of threonine 303 in P450 2E1 inactivation. Biochemistry 43:11942-11952.
3. Bumpus NN, Sridar C, Kent UM, and Hollenberg PF (2005) The naturally occurring cytochrome P450 (P450) 2B6.4 mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos 33:795-802.
4. Chang TK, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53:1155-1166.
5. Chatterjee P and Franklin MR (2003) Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31:1391-1397.
6. Edwards IR and Aronson JK (2000) Adverse drug reactions: definitions, diagnosis and management. Lancet 356:1255-1259.
7. Einarson TR (1993) Drug-related hospital admissions. Ann Pharmacother 27:832-840.
8. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
9. Foroozesh M, Primrose G, Guo Z, Bell LC, Alworth WL, and Guengerich FP (1997) Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem Res Toxicol 10:91-102.
10. Harleton E, Webster M, Bumpus NN, Kent UM, Rae JM, and Hollenberg PF (2004) Metabolism of N,N′,N″-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. J Pharmacol Exp Ther 310:1011-1019.
11. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression in human liver. Arch Biochem 376:206-216.
12. Hanna IH, Roberts ES, and Hollenberg PF (1998) Molecular basis for the difference in lidocaine binding and the regioselectivity of oxidation by cytochrome P450 2B1 and 2B2. Biochemistry 37:311-318.
13. Harris M and Montaner JS (2000) Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol 10:217-229.
14. Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
15. Hesse LM, von Moltke LL, Shader RI, and Greenblatt DJ (2001) Ritonavir, efavirenz and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 29:100-102.
16. Kent UM, Juschyshyn MI, and Hollenberg PF (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215-243.
17. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, and Hollenberg PF (2002) Effect of 17-α-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 300:549-558.
18. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, and Zanger UM (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861-873.
19. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
20. Lazarou J, Pomeranz BH, and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients - a meta analysis of prospective studies. J AM Med Assoc 279:1200-1205.
21. Lin HL, Kent UM, and Hollenberg PF (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154-164.
22. Miksys S and Tyndale RF (2004) The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 36:313-333.
23. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, and Christ DD (1999) Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319-1333.
24. Obach RS, Cox LM, and Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33:262-270.
25. Phillips KA, Veenstra DL, Oren E, Lee JK, and Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J Am Med Assoc 286:2270-2279.
26. Pirmohamed M and Park BK (2003) Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 192:23-32.
27. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
28. Roberts ES, Hopkins NE, Foroozesh M, Alworth WL, Halpert JR, and Hollenberg PF (1997) Inactivation of cytochrome P450s 2B1, 2B4, 2B6 and 2B11 by arylalkynes. Drug Metab Dispos 25:1242-1248.
29. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, and Soriano V (2005) Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 40:1358-1361.
30. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, and Telenti A (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15:1-5.
31. Roy P, Yu LJ, Crespi CI, and Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666.
32. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:67-68.
33. Sharma U, Roberts ES, and Hollenberg PF (1996) Formation of metabolic intermediate complex of cytochrome P4502B1 by clorgyline. Drug Metab Dispos 24:1247-1253.
34. Thum T and Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355:979-983.
35. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, and Oka S (2004) Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322-1326.
36. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, and Pelkonen O (2004) Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626-631.
37. Tychopoulos M, Corcos L, Genne P, Beaune P, and de Waziers I (2005) A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Ther 12:497-508.
38. Ward BA, Gorski CJ, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as substrate marker of 2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.